Stem Cell Therapy advancements, page-367

Might be a good idea to check the news to the ASX/company first, before posting. As others have said, that's just the end of September quarterly Appendix 4C results.

Lets keep this thread to stem cell therapy developments guys. In that vein, yet another positive development with a large autologous stem cell therapy trial:

https://www.medpagetoday.com/meetingcoverage/ashhematology/102227

"Among 229 patients with newly diagnosed disease who had responded to induction therapy, progression-free survival (PFS) rates at 3 years reached 79% with high-dose chemotherapy plus autologous stem-cell transplant (ASCT) consolidation, as compared with 53% with a non-myeloablative chemoimmunotherapy regimen (HR 0.405, 95% CI 0.252-0.650, P=0.0002), reported Gerald Illerhaus, MD, of Klinikum Stuttgart hospital in Germany."

Its almost hilarious that this stock trades down here given its IP in autologous tendon stem cells, collaborations, announced results, and literally every person in the world suffering from degenerative tendons. I have literally lost count of the number of favourable trials and regulatory developments I have posted in autologous stem cell therapies on this thread. A very poor reflection on the information efficiency of equity markets that OCC, even with its Bio Horizons' deal still trades low 40's yet again.